Friday 6 November 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue: −2.20%
EPS: +530.3%
Free cash flow: +16.3%
Total debt: +11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%

Follow CRL

Alert me

Market cap: $14.9B
P/E: 300×
Fwd P/E: 89.2×
Dividend yield: —
F-score: 5/9
Altman Z: 2.40
Beneish M: −3.11
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Charles River Laboratories International, Inc. (CRL) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2024: revenue by segment, and margins
DSA	2,451	60.53%
RMS	829	20.48%
Manufacturing	769	19.00%
Gross margin		32.88%
Operating margin		5.61%
Pre-tax margin		2.30%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cost of services provided (excluding amortization of intangible assets)	3,250 80.94%	3,304 81.58%	3,440 83.31%	3,217 80.91%	2,756 77.84%	2,296 78.53%	2,029 77.42%	1,688 74.49%	1,298 69.89%	1,131 67.25%
Cost of products sold (excluding amortization of intangible assets)	765 19.06%	746 18.42%	689 16.69%	759 19.09%	785 22.16%	628 21.47%	592 22.58%	578 25.51%	559 30.11%	551 32.75%
Revenue	4,015	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cost of services provided (excluding amortization of intangible assets)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Cost of products sold (excluding amortization of intangible assets)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
DSA	2,403 59.84%	2,451 60.53%	2,616 63.34%	2,447 61.55%	2,107 59.52%	1,837 62.84%	1,619 61.76%	1,317 58.11%	980 52.76%	837 49.75%	612 44.90%	538 41.48%	432 37.10%	409 36.20%	—	—	—
RMS	846 21.07%	829 20.48%	792 19.19%	739 18.59%	—	—	—	—	—	—	—	—	—	—	—	—	—
Manufacturing	766 19.09%	769 19.00%	721 17.47%	790 19.86%	742 20.97%	515 17.63%	465 17.75%	430 18.96%	384 20.67%	351 20.86%	281 20.59%	256 19.71%	222 19.03%	199 17.62%	—	—	—
RMS	—	—	—	739 18.59%	690 19.50%	571 19.53%	537 20.49%	520 22.93%	494 26.57%	494 29.38%	470 34.51%	504 38.81%	511 43.87%	522 46.18%	705 61.74%	667 58.85%	660 56.33%
Emd	—	—	—	—	—	—	—	—	—	—	—	—	—	105 9.33%	83 7.27%	72 6.33%	103 8.76%
Preclinical Services	—	—	—	—	—	—	—	—	—	—	—	—	—	—	437 38.26%	466 41.15%	512 43.67%
Eliminations	—	—	—	(739) (18.59%)	—	—	—	—	—	—	—	—	—	(105) (9.33%)	(83) (7.27%)	(72) (6.33%)	(103) (8.76%)
Revenue	4,015	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681	1,363	1,298	1,166	1,130	1,143	1,133	1,172

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
DSA	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Segment operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
RMS	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Manufacturing	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
RMS	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Preclinical Services	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Unallocated Amount to Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reportable Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
U.S.	2,142 53.34%	2,240 55.31%	2,347 56.85%	2,342 58.91%	1,934 54.64%	1,627 55.65%	1,471 56.12%	1,268 55.94%	959 51.64%	850 50.58%	659 48.37%	589 45.35%	551 47.30%	535 47.35%	545 47.71%	536 47.27%	576 49.13%
Europe	1,103 27.46%	1,078 26.62%	1,077 26.08%	1,032 25.96%	1,036 29.28%	829 28.36%	726 27.71%	644 28.42%	570 30.67%	521 30.98%	435 31.94%	446 34.39%	354 30.35%	342 30.24%	348 30.50%	327 28.89%	327 27.93%
Canada	501 12.48%	482 11.90%	487 11.80%	399 10.03%	339 9.58%	306 10.47%	272 10.38%	206 9.11%	200 10.79%	194 11.55%	172 12.64%	163 12.60%	162 13.93%	160 14.17%	159 13.91%	181 15.97%	188 16.06%
Asia Pacific	205 5.11%	197 4.86%	201 4.86%	193 4.85%	223 6.30%	155 5.30%	146 5.58%	142 6.29%	126 6.81%	115 6.82%	96 7.04%	50 3.85%	59 5.09%	78 6.88%	76 6.65%	74 6.52%	71 6.05%
Other	65 1.62%	53 1.30%	17 0.41%	10 0.25%	7 0.21%	6 0.21%	6 0.21%	6 0.25%	2 0.09%	1 0.07%	0 0.00%	—	—	—	—	—	—
Other Non U.S.	—	—	—	—	—	—	—	—	—	—	—	49 3.81%	39 3.32%	15 1.37%	14 1.23%	15 1.35%	10 0.83%
Revenue	4,015	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681	1,363	1,298	1,166	1,130	1,143	1,133	1,172

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Remaining performance obligations	Q2 FY2026	$699.9M	$727.3M	−3.77%

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q3 FY2018	Q2 FY2018	Q1 FY2018
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.